Criticalkare Pharma

Evenity Injection contains the active ingredient Romosozumab, a humanized monoclonal antibody that promotes bone formation while simultaneously inhibiting bone resorption. It belongs to the anti-osteoporotic agents class and is primarily indicated for the treatment of osteoporosis in postmenopausal women who are at high risk of fractures. By increasing bone mineral density and strength, Injection Evenity reduces the risk of both vertebral and non-vertebral fractures in patients with severe osteoporosis. This treatment is particularly recommended for individuals who have not responded well to other osteoporosis therapies.
Evenity Injection uses include reducing the likelihood of fractures in postmenopausal women who have experienced multiple fractures or are at risk due to significantly low bone mass. It is administered as a subcutaneous injection once a month for 12 months. Evenity injection dose is typically 210 mg per month, provided as two consecutive injections. Patients are usually transitioned to anti-resorptive therapy following the completion of the 12-month course to maintain the benefits gained.
Although effective, it is essential to be aware of Evenity injection side effects, which may include joint pain, headache, injection site reactions, and, in rare cases, an increased risk of cardiovascular events. Patients with a history of heart attack or stroke should avoid this medication. Evenity injection instructions must be followed carefully to minimize potential adverse effects. It is advised to monitor calcium and vitamin D levels during treatment to prevent hypocalcemia. For those considering this treatment, Evenity injection reviews highlight its effectiveness in improving bone density and reducing fractures. However, it is essential to consult a healthcare provider to assess individual risks and benefits, as the cost of Evenity injection can be high.

Uses
Treatment of osteoporosis in postmenopausal women at high risk of fractureReducing the incidence of vertebral and non-vertebral fractures

Storage
Store the injection in the refrigerator between 2°C to 8°C.Do not freeze.

Side Effects
Joint painHeadacheInjection site reactionsMuscle painFatigueCardiovascular events such as heart attack or strokeHypocalcemia (low calcium levels)

Alzumab L 100mg Injection contains an active component as Itolizumab. It is a monoclonal antibody used to treat certain autoimmune conditions, particularly moderate to severe psoriasis and rheumatoid arthritis. Monoclonal antibodies are synthetic proteins designed to mimic the immune system's ability to target specific substances in the body. This medication was originally developed in Cuba and has been approved for moderate to severe plaque psoriasis. It has shown promising results in studies for rheumatoid arthritis as well. This medication has generally shown good tolerability in clinical trials. Common side effects are usually mild to moderate, including infusion-related reactions, headache, dizziness, and mild gastrointestinal symptoms. Serious adverse events are relatively rare.
Individuals with known hypersensitivity or severe allergic reactions to Alzumab L 100mg Injection or any of its components should avoid its use. This medication may impact the immune system, increasing the risk of infections. Patients with active infections may need to have their condition managed and the infection resolved before starting treatment. Live vaccines should be avoided during treatment since they may interfere with effectiveness. Patients should consult their healthcare provider about appropriate vaccination schedules. Individuals with certain pre-existing conditions, such as immunosuppression or a history of severe infections, may require caution due to the potential risk of further immunosuppression.

Uses
Chronic plaque psoriasisRheumatoid arthritis

Storage
Store at refrigerator temperature between 2°C to 8°C (36°F to 46°F).Keep away from moisture, heat, and light.
It should not be frozen.

Side Effects
Severe allergic reactions, including rash, itching, swelling, severe dizziness, or difficulty breathingInfectionsNeurological events (seizures)Liver problemsAnemia (decreased red blood cell)Decreased white blood cellHeadacheDizzinessNausea or vomitingAbdominal discomfortDiarrheaFatigueRash or itching at the injection siteInfusion-related reactions (e.g., fever, chills, flushing)